scholarly journals Potential Tumor Biomarkers for Ovarian Cancer

10.5772/28397 ◽  
2012 ◽  
Author(s):  
Ryan Serio ◽  
Blase Billack
Keyword(s):  
Ovarian Cancer ◽  
Tumor Biomarkers

scholarly journals Diagnostic value of tumor biomarkers CA125 and CA72-4 in differentiation of epithelial ovarian cancer and endometrioma

2018 ◽  
Vol 29 (8) ◽  
Author(s):  
Jafari Shobeiri Mehri ◽  
Sepasi Farnaz ◽  
Dastranj Tabrizi Ali ◽  
Mostafa Gharabaghi Parvin ◽  
Ouladsahebmadarek Elaheh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Diagnostic Value ◽  
Tumor Biomarkers

scholarly journals Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Brandon-Luke L. Seagle ◽  
Kevin H. Eng ◽  
Judy Y. Yeh ◽  
Monica Dandapani ◽  
Emily Schiller ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Tumor Biomarkers

Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells

2005 ◽  
Vol 83 (6) ◽  
pp. 457-467 ◽  
Author(s):  
Pengming Sun ◽  
Jalid Sehouli ◽  
Carsten Denkert ◽  
Alexander Mustea ◽  
Dominique Könsgen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Nuclear Receptors ◽  
Ovarian Cancer Cells ◽  
Tumor Biomarkers ◽  
Orphan Nuclear Receptors

scholarly journals Ovarian Cancer Immunotherapy and Personalized Medicine

2021 ◽  
Vol 22 (12) ◽  
pp. 6532
Author(s):  
Susan Morand ◽  
Monika Devanaboyina ◽  
Hannah Staats ◽  
Laura Stanbery ◽  
John Nemunaitis
Keyword(s):  
Ovarian Cancer ◽  
Tumor Infiltrating Lymphocytes ◽  
Tumor Biomarkers ◽  
Future Directions ◽  
Tumor Mutation Burden ◽  
Mutation Burden ◽  
Target Treatment ◽  
Study Designs ◽  
Infiltrating Lymphocytes

Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome
Sign in / Sign up

Export Citation Format

Share Document